| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
195,929 |
270,693 |
314,053 |
651,089 |
| Total Sell Value |
$16,425,801 |
$23,384,210 |
$27,285,232 |
$61,044,052 |
| Total People Sold |
5 |
5 |
6 |
7 |
| Total Sell Transactions |
13 |
20 |
26 |
55 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2019-03-25 |
4 |
AS |
$87.86 |
$351,440 |
D/D |
(4,000) |
323,211 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2019-03-25 |
4 |
OE |
$14.39 |
$57,560 |
D/D |
4,000 |
327,211 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2019-03-22 |
4 |
D |
$88.05 |
$316,804 |
D/D |
(3,598) |
61,083 |
|
- |
|
| Mueller Brian |
SVP, Corporate Controller |
• – – |
2019-03-22 |
4 |
D |
$88.05 |
$36,541 |
D/D |
(415) |
16,613 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2019-03-22 |
4 |
D |
$88.05 |
$316,804 |
D/D |
(3,598) |
51,131 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2019-03-22 |
4 |
D |
$88.05 |
$308,263 |
D/D |
(3,501) |
93,258 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2019-03-22 |
4 |
D |
$88.05 |
$513,860 |
D/D |
(5,836) |
130,468 |
|
- |
|
| Davis George Eric |
EVP, General Counsel |
• – – |
2019-03-22 |
4 |
D |
$88.05 |
$291,357 |
D/D |
(3,309) |
75,253 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2019-03-22 |
4 |
D |
$88.05 |
$1,155,832 |
D/D |
(13,127) |
323,211 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2019-03-21 |
4 |
AS |
$89.62 |
$406,634 |
D/D |
(4,519) |
54,729 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2019-03-19 |
4 |
AS |
$93.07 |
$346,965 |
D/D |
(3,728) |
59,248 |
|
- |
|
| Davis George Eric |
EVP, General Counsel |
• – – |
2019-03-19 |
4 |
AS |
$93.92 |
$742,625 |
D/D |
(7,907) |
78,562 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2019-03-19 |
4 |
OE |
$14.39 |
$14,390 |
D/D |
1,000 |
336,338 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2019-03-18 |
4 |
AS |
$94.09 |
$902,982 |
D/D |
(9,597) |
136,304 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2019-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,370 |
62,976 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2019-03-15 |
4 |
D |
$94.53 |
$677,686 |
D/D |
(7,169) |
53,606 |
|
- |
|
| Mueller Brian |
SVP, Corporate Controller |
• – – |
2019-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,780 |
17,028 |
|
- |
|
| Mueller Brian |
SVP, Corporate Controller |
• – – |
2019-03-15 |
4 |
D |
$94.53 |
$108,615 |
D/D |
(1,149) |
11,248 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2019-03-15 |
4 |
AS |
$94.40 |
$377,600 |
D/D |
(4,000) |
335,338 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2019-03-15 |
4 |
OE |
$14.39 |
$57,560 |
D/D |
4,000 |
339,338 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2019-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
34,780 |
335,338 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2019-03-15 |
4 |
D |
$94.53 |
$2,660,358 |
D/D |
(28,143) |
300,558 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2019-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,370 |
64,681 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2019-03-15 |
4 |
D |
$94.53 |
$683,168 |
D/D |
(7,227) |
55,311 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2019-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,630 |
96,759 |
|
- |
|
2578 Records found
|
|
Page 22 of 104 |
|
|
1.44 (1.6%) 
